Axonis Therapeutics: $115 Million (Series A) Raised To Develop Novel Neuromedicines
By Amit Chowdhry ● Nov 8, 2024
Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced the completion of an oversubscribed $115 million Series A financing. The proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. Cormorant Asset Management and venBio Partners co-led the financing with significant investments from Sofinnova Investments, MRL Ventures Fund, Perceptive Advisors, Lumira Ventures and Solasta Ventures. Eos Bioinnovation, Hatteras Venture Partners, SCI Ventures, Alexandria Venture Investments, Tachyon Ventures, BoxOne, Iaso Ventures and Pathway Bioventures also participated in the financing.